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Background: The increase in life expectancy of HIV-infected patients has driven increased costs due to life-long HIV
treatment and concurrent age-related comorbidities. This population-based study aimed to investigate the burden
of chronic diseases and health costs for HIV+ subjects compared to the general population living in Brescia Local
health Agency (LHA) over a 12-year period.
Methods: LHA database recorded diagnoses, deaths, drug prescriptions and health resource utilization for all
residents during 2003–2014. We estimated HIV prevalence and incidence, HIV-related mortality as well as prevalence
of chronic diseases in HIV+ subjects. Observed/expected ratio of chronic diseases was calculated by indirect
standardization with the general population as reference. Direct cost of HIV care and determinants were estimates
across the period.
Results: HIV prevalence increased from 220 to 307 per 100 000 person-years while incidence decreased from 16.1
to 10.8 per 100 000 person-years from 2003 to 2014. Prevalence of most comorbidities increased over time but it
reduced significantly (annual mean change − 0.7 %) when adjusting for age and gender. Observed to expected
ratio for each chronic disease in HIV+ subjects decreased over time. Cost of HIV+ cures increased (+25 %) mainly
due to cost for drugs (+50 %) but it stabilized in recent years. CD4+ cell count at the time of diagnosis was an
important predictor of cost for HIV management.
Conclusions: Expenditures for HIV-infection are driven mainly by drugs cost and they have increased overtime.
However, our findings suggest that spending on public health for HIV care can improve prognosis of HIV-infected
patients, reduce transmission of HIV infection and reduce the global burden of chronic diseases, leading to a
reduction of HIV global cost in the medium-long time.
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During the past twenty years, antiretroviral therapy (ART)
introduction has dramatically modified the natural evolution
of HIV infection, with decreased morbidity and increased
survival of infected patients [1–4]. Due to the important de-
crease in mortality and consequent aging of HIV-infected
people, HIV infection is responsible for an increasing bur-
den on healthcare services. Treating with ART has resulted
in a continuous increase of the total treatment cost, mainly
because of the appearance of new, more effective but more
expensive drugs during last years [5, 6]. The increase in life
expectancy of HIV-infected patients [7, 8] has also driven in-
creased costs due to life-long HIV treatment and concurrent
age-related comorbidities [9].
In our previous population-based study performed in a
province of North Italy with high HIV prevalence, HIV in-
fection ranked third among chronic diseases in order of
total cost per patient to the National Health Service, with
a mean cost of 9 894€ in 2007 (ranging from 8 104€ for
HIV–infected patients without comorbidities to 12 013€
for HIV infection plus cancer) [10]. However, an update of
the estimates of cost-of-care of HIV+ subjects is needed
because of recent changes of HIV epidemiologic pattern
and guidelines of treatment, which have moved toward
treating HIV+ patients earlier in the course of disease and
have added newer, more effective and tolerated but also
more expensive drugs [11].
The aim of this population-based study was to investi-
gate the burden of chronic diseases and the direct health
costs and resource allocation for HIV+ subjects compared
to the general population living in the Brescia Local Health
Authority (LHA) over a 12-year period, from 2003 to 2014.
Methods
Setting
This study was conducted in the Brescia Province,
located in Lombardy Region (northern Italy) in the
period 2003–2014.
The Spedali Civili General Hospital in Brescia is one of
the largest public hospitals in Italy, and is also the refer-
ence hospital for the local School of Medicine, University
of Brescia (University Hospital). It includes the only
tertiary, referral center of infectious diseases and HIV of
the area. In Italy, the National Health Service (NHS)
provides universal coverage and is structured on three
organizational levels: the central (the Ministry of Health),
regional and local levels (Local Health Agency. LHA). In
Italy, hospital service providers are paid on a fee-for-
service basis, which is directly related to a system of
Diagnosis-Related Groups (DRGs) [12]. Primary care and
other out-patient services are based on a co-payment
system for drugs, laboratory tests and any services pro-
vided to patients affected by chronic diseases. However,
these services are fee-exempted for HIV+ subjects.The study protocol was approved by the provincial
Ethical Review Board. Written informed consent was
obtained by all the patients enrolled.
Population
We included in the analysis all residents in Brescia LHA
registered in the Regional Health Service from 2003 to
2014. Non-documented migrants and non-EU citizens were
excluded, as their access to care and utilization of health re-
sources cannot be properly assessed as they can only access
to emergency treatment under semi-anonymous condition.
HIV infection was identified using the following two
sources, as previously described [10]:
 Brescia LHA electronic database. HIV diagnosis was
based on HIV-related opportunistic illness requiring
hospital admission (ICD9 = 042 or V08 diagnoses), re-
ceiving HIV drugs prescription or HIV reimbursement
code assigned by the general practitioner or a specialist.
 Clinical charts and electronic databases of the
Department of Infectious and Tropical Diseases,
University of Brescia and Brescia Spedali Civili General
Hospital. HIV diagnosis was based on positive HIV-1
or HIV-2-antibody test or positive HIV RNA.
For each year, we analyzed: a) HIV+ prevalent cases in-
cluding subjects with HIV diagnosis who were present
in the Brescia LHA database, independently of the year
of HIV diagnosis; and b) HIV+ incident cases including
subjects with HIV diagnosis in that year.
The Brescia local health agency database
The Brescia Local Health Agency database (BLHADB) is a
comprehensive and integrated information system includ-
ing several databases tracking and listing all the health
services provided by the NHS for each individual of the
resident population [10].
Prescription of specific drugs is monitored for each indi-
vidual by the BLHADB using the Anatomic and Thera-
peutic Chemical Classification (ATC) [13]. Each individual’s
consumption of drugs is converted into a total number of
daily defined doses (DDDs), according to the World Health
Organization Collaborating Centre for Drug Statistics and
Methodology [13]. Drug consumption data presented in
DDDs provide a rough estimate of consumption and not
an exact picture of each patient’s actual use. DDDs provide
a fixed unit of measurement independent of price and for-
mulation that enable to assess trends in drug consumption
and to perform comparisons between population groups.
In this analysis we identified 10 families of chronic
diseases using a set of ICD9-CM codes (see Additional
file 1: Table S1). Each subject was considered to have a
chronic disease if he had had Access to Continuity of
Care (ACC) for one or more chronic diseases of interest
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the following criteria:
 receiving in-hospital or out-patient services with an
ICD9-CM code for a chronic disease;
 receiving drugs for chronic diseases above a predefined
DDD threshold (e.g. >10 % DDD of insulin or >30 %
DDD of oral anti-diabetic drugs to define diabetes);
 having a chronic disease reimbursement code
assigned by the general practitioner or a specialist;
 being admitted to a residential care or psychiatric
facility.
ACC for chronic diseases has therefore been considered
a proxy for disease prevalence.
Outcomes and covariates
Information on vital status and date and cause of death
were obtained from a record-linkage with the LHA Mor-
tality Registry, based on each individual’s national regis-
tration code.
For each year of follow-up, we retrieved the presence of
chronic diseases from BLHADB. The chronic diseases of
interest evaluated were the following: cardiovascular
diseases, liver diseases, dyslipidemia, diabetes, cancer,
esophagus gastric duodenum diseases, neuropathies,
severe psychiatric disorders, bronco-pneumopathy and
kidney failure.
HIV infected persons who were at any time on anti-
retroviral treatment during the year were classified as
‘on antiretroviral treatment’ according to either hospital
or LHA drug databases.
We evaluated the direct costs for each HIV+ subject, cal-
culated as the sum of inpatient hospital costs and out-
patients costs. Inpatient hospital costs (for both in-patient
and day-care admissions) were based on DRG system as
previously described [10]. Costs of out-patient consultations
and examinations (laboratory and clinical imaging) were cal-
culated based on the official standard costs assigned by the
Italian Ministry of Health. All costs were annualized and
expressed in nominal terms for the year in which they were
incurred. Indirect Costs were not evaluated.
For patients followed by University Hospital we also
retrieved CD4+ cell count at HIV diagnosis.
Statistical analysis
HIV incidence and prevalence rates were calculated
using incident and prevalent cases as numerators, re-
spectively, and population living in the Brescia LHA
during the period as denominator. Annual mean change
was calculated using multivariate Poisson regression
adjusted for age and gender.
We calculated the prevalence of chronic diseases in 3
years periods across the follow-up. To evaluate the temporaltrend of risk of having a chronic disease, we performed an
age-and gender-adjusted Poisson regression model for each
chronic disease considered in this study. Results were
expressed in terms of percentage of annual mean change of
risk ([risk ratio-1]*100).
Prevalence of, and mortality for chronic diseases in HIV+
subjects were compared with those observed in the LHA
general population using indirect standardization.
Standardized prevalence ratios (SPRs) and standard-
ized mortality ratios (SMRs) were computed adjusting
for age and gender. The SPRs and SMRs and their
95 % confidence intervals (95 % CIs) were calculated
using the Byar’s approximation of Poisson model. The
SPRs were calculated for each chronic disease and for
at least one, for each 3 year calendar period. The
SMRs were also calculated for specific causes of death
(HIV/AIDS, liver disease, suicide and cancer).
Association of chronic diseases, age, gender, period of
follow-up and CD4+ cell count at baseline with per capita
cost was evaluated by using multivariate regression
models with per capita cost as the dependent variable with
a bootstrap technique (1000 replications).
All statistical tests were two-sided, assumed a level of
significance of 0.05 and were performed using Stata 12 soft-
ware (Stata Statistics/Data Analysis 12.0-Stata Corporation,
College Station, TX, USA).
Results
Characteristics of the HIV-infected population in the
BLHA DB
From 2003 to 2014, a total of 4 621 subjects were identi-
fied as receiving care for HIV infection and included in
this study. The main characteristics of the HIV-infected
population are shown in Table 1. The number of HIV+
subjects increased from 2 302 in 2003 to 3 594 in 2014
with an increase in prevalence from 220 per 100 000
person-years in 2003 to 307 per 100 000 in 2014 (annual
mean change +2.5 %, p < 0.001). We observed a decrease
of HIV incidence rate from 16.1 to 10.8 per 100 000
person-years, (annual mean change − 4.5 %, p < 0.001),
and of the overall mortality rate from 25.6 to 13.4 per
1000 HIV+ subjects, (annual mean change − 8.7 %, p <
0.001), with 542 deaths in the period (71 deaths for liver
disease, 70 for cancer and 19 for suicide).
Among all HIV+ cases, the mean age increased from
40.1 years in 2003 to 47.8 years in 2014, so as prevalence of
non-Italian citizens (from 7.0 % to 13.4 %) and of subjects
on ART treatment (from 67.3 % to 82.5 %) (p < 0.001 for
each variable). Considering only the new HIV+ cases, the
mean age was stable around 40 years, but the proportion of
females decreased over time (from 30.4 % to 21.4 %).
The distribution of CD4+ cell count at baseline in new
HIV+ cases is shown in Table 2. About half of the patients
(54 %) with newly diagnosed HIV infection had a late
Table 1 Demographic and epidemiological characteristic of HIV+ subjects living in the Brescia Local Health Authority (LHA)
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
Resident population (n) 1045478 1055256 1070896 1093708 1111659 1136817 1149520 1157391 1164382 1168168 1170158 1170655
Non-Italian citizens (%) 6.8 7.4 8.4 10.0 10.6 12.4 13.4 13.9 14.2 14.4 14.4 14.2
All patients receiving care for HIV infection
Prevalence cases (n) 2302 2482 2651 2736 2935 2993 3181 3277 3369 3439 3527 3594
Prevalence rate per
100 000 person-years
220 235 248 250 264 263 277 283 289 294 301 307
Mean age (years) 40.1 40.7 41.3 42.1 42.8 43.7 44.4 45.1 45.8 46.4 47.2 47.8
Female (%) 28.6 28.4 29.2 29.6 29.5 29.3 29.9 30.1 29.9 29.9 29.7 29.5
Non-Italian citizens (%) 7.0 8.2 9.3 10.1 10.7 10.8 12.0 12.5 13.4 13.9 14.0 13.4
On antiretroviral therapy
treatment (%)
67.3 70.7 70.1 73.9 75.5 76.8 78.1 79.3 80.2 82.0 82.0 82.5
New cases (n) 168 167 188 117 153 125 132 122 131 111 133 126
Incidence rate per
100 000 person-years
16.1 15.8 17.6 10.7 13.8 11.0 11.5 10.5 11.3 9.5 11.4 10.8
Mean age (years) 39.2 38.5 38.4 38.7 40.9 42.2 41.1 40.3 38.7 39.2 41.2 38.8
Female (%) 30.4 25.7 29.3 29.9 28.1 20.0 31.1 27.9 27.5 23.4 24.8 21.4
Non-Italian citizens (%) 18.5 16.8 19.7 24.8 20.9 19.2 31.1 23.8 31.3 27.9 29.3 23.8
Mortality (n) 59 46 46 37 48 47 48 46 46 43 28 48
Mortality rate per
1000 HIV+subjects
25.6 18.5 17.4 13.5 16.4 15.7 15.1 14.0 13.7 12.5 7.9 13.4
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period without substantial change over time (p > 0.1).
Prevalence of chronic diseases
The prevalence of chronic diseases in HIV+ subjects ac-
cording to observation period is shown in Table 3. The
prevalence of at least one chronic disease decreased from
33.9 % in 2003 to 29.8 % in 2014 (annual mean change
after adjustment for age and gender − 0.7 %; p < 0.001).
Considering chronic diseases separately, we observed
statistically significant trends, adjusting for age and gender
of increasing of prevalence of dyslipidemia (annual mean
change +5.5), diabetes (+1.6 %), and gastrointestinal
diseases (+5.7 %) and decreasing prevalence of liver
diseases (−4.8 %) and chronic respiratory diseases
(−5.6 %). The crude prevalence of cardio-cerebrovascular
diseases increased over time from 13.6 % in 2003 toTable 2 CD4+ cell count distribution of the new cases* of HIV infec
2003–2005 n (%) 2006–2008 n (%)
New cases 598 422
CD4+ cell count mm3
< 200 196 (32.8) 131 (31.0)
200–349 113 (18.9) 98 (23.2)
350–499 116 (19.4) 75 (17.8)
≥ 500 165 (27.6) 116 (27.5)
missing 8 (1.3) 2 (0.5)
*new cases were categorized in different periods according to the first access to ho20.7 % in 2014 but this trend was not significant when
adjusting for age and sex.
Comparison with the Brescia LHA general population
Figure 1 shows SPRs for chronic diseases using Brescia
LHA population as the reference. The prevalence of any
chronic disease was higher in HIV+ subjects than the
general population, with total SPRs ranging from 1.15 to
6.18. However, SPRs decreased for all chronic disease
except for dyslipidemia over time.
HIV+ subjects had a higher mortality than the LHA gen-
eral population in the period, showing SMR of 5.94 (95 %
CI 6.47–7.03). The SMR for all causes showed a steady de-
crease from 9.77 (95 % CI 11.53–13.53) in 2003–2005 to
3.43 (95 % CI 4.15–4.96) in 2012–2014. The mortality
rates for liver disease, suicide and cancer were higher in
HIV+ subjects than the LHA general population withtion at HIV diagnosis by 3 years-time periods
2009–2011 n (%) 2012–2014 n (%) Total
403 316 1739
136 (33.7) 112 (35.4) 575 (33.1)
96 (23.8) 62 (19.6) 369 (21.2)
68 (16.9) 62 (19.6) 321 (18.5)
94 (23.3) 77 (24.4) 452 (26.0)
9 (2.2) 3 (0.9) 22 (1.3)
spital care
Table 3 Prevalence of chronic diseases in HIV population according to 3-year-time periods
Chronic diseases 2003–2005 2006–2008 2009–2011 2012–2014 Trend Annual mean changea p-value
Subjects observed in the period (n) 2846 3211 3604 3855
Cardio-Cerebrovascular diseases (n) 387 511 614 798 ≈ +0.1 % NS
Prevalence (%) 13.6 15.9 17.0 20.7
Liver diseases (n) 573 640 547 428 ↓ −4.8 % <0.001
Prevalence (%) 20.1 19.9 15.2 11.1
Dyslipidemia (n) 107 198 263 340 ↑↑ +5.5 % <0.001
Prevalence (%) 3.8 6.2 7.3 8.8
Diabetes (n) 100 149 198 248 ↑ +1.6 % 0.042
Prevalence (%) 3.5 4.6 5.5 6.4
Cancer (n) 158 182 232 242 ≈ +0.1 % NS
Prevalence (%) 5.6 5.7 6.4 6.3
Gastrointestinal diseases (n) 75 95 130 206 ↑↑ +5.7 % <0.001
Prevalence (%) 2.6 3.0 3.6 5.3
Neuropathies (n) 110 136 146 166 ≈ +0.2 % NS
Prevalence (%) 3.9 4.2 4.1 4.3
Severe psychiatric disorders (n) 96 118 141 129 ≈ +1.1 % NS
Prevalence (%) 3.4 3.7 3.9 3.3
Chronic respiratory diseases (n) 129 135 122 154 ↓↓ −5.6 % <0.001
Prevalence (%) 4.5 4.2 3.4 4.0
Kidney failure (n) 27 29 41 54 ≈ +2.2 % NS
Prevalence (%) 0.9 0.9 1.1 1.4
At least one chronic disease (n) 966 1096 1150 1148 ↓ −0.7 % 0.006
Prevalence (%) 33.9 34.1 31.9 29.8
aAnnual mean change was calculated using multivariate Poisson regression models adjusted for age and gender with in offset the logarithm of general population.
NS p > 0.05
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9.21) and 1.60 (95 %, CI 2.06–2.60), respectively.
Resource utilization and costs
The total health care cost for HIV+ subjects has increased
substantially, from a mean of 28.5 million€ per year in 2007
to 36.5 million€ per year in 2014 (+22 %). The overall cost
for public health care of subjects with chronic diseases in
the Brescia LHA general population in 2014 are shown in
Additional file 1: Table S2. HIV infection ranked as the third
most costly chronic disease in the Brescia LHA in 2014.
Per capita health care costs by 3 years-time periods are
shown in Table 4. Per capita costs increased from 8 271€
in 2003–05 to 10 945€ in 2009–11 (+32 %) with a slight
decrease in 2012–14 (+ 25 % from the first to the last inter-
val). The most important item of expenditure was ART,
that increased from 5 079€ (61.4 % of the total per capita
cost) in 2003–2005 to 7 562€ (72.9 %) in 2012–2014 (+
49 %). Also in new HIV+ cases, the ART cost increased
over time from 2 522€ (31.6 % of the total per capita cost)
in 2003–2005 to 3 496€ (35.9 %) in 2012–2014 (+39 %). Of
interest, in-patient costs decreased substantially (−28 %) inHIV+ subjects on ART, over the study period. However, in
new HIV+ cases the most costly item of expenditure was
in-hospital cost that was stable over time.
We also evaluated the association between, age, gender,
period of follow-up, CD4+ cell count at baseline and
chronic diseases with per capita cost using multivariate re-
gression models (Table 5). The per capita cost was posi-
tively associated with age (+36€ every year of age), years of
follow-up and CD4+ cell count at baseline (+2 452€ for
subjects with CD4+ cell count <200 mm3 at baseline
respect to subjects with CD4+ cell count ≥ 500 mm3) and
the presence of chronic diseases. In particular, we ob-
served an increase of 3 700€ for subjects with, compared
to those without, at least one chronic disease. Kidney
failure, psychiatric diseases and cancer were the most ex-
pensive comorbidities, with an increase of per capita cost
of 13 665€, 8 172€ and 7 557€, respectively.Discussion
This population-based study carried out in a Health Care
District of North Italy is an extension of a previously
Fig. 1 Standardized prevalence ratios (SPRs) and their 95 % confidence intervals (95 % CIs) of chronic diseases using Local Health Authority
general population as reference. The filled segments of the horizontal bars represent the upper limit of the 95 % CI of the SPRs, whereas the
open segments represent the lower limit
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costs in 2003–2007 up to 2014 [10].
The prevalence of HIV infection increased from 220
to 307 per 100 000 person-years (+2.5 % annual mean
change) while incidence decreased from 16 to 11 per
100 000 person-years (-4.5 % annual mean change) and
mortality decreased from 25.6 to 13.4 per 1000 person-
years (−8.7 % annual mean change). Concomitantly with
aging of the cohort of HIV-infected patients, the preva-
lence of most chronic diseases increased across time and
was higher than that of LHA general population. How-
ever, the observed to expected ratios (SPRs) in HIV+
subjects decreased over time for each chronic disease
except dyslipidemia. Average per capita total cost of HIV
infection increased from 2003 to 2014 (+25 %) mainly
due to cost for ART (+49 %). Immunodeficiency level atthe time of HIV diagnosis had an important weight on
healthcare spending: the per capita cost for patients with
CD4+cell count <200 mm3 was 2 106€ more than pa-
tients with CD4+cell count >500 mm3.
There is mounting evidence that an increase of use on
HIV healthcare services leads to a reduction in both
mortality and HIV transmission and therefore to reduc-
tion of HIV incidence [14–16]. Accordingly, we found an
increase of HIV management costs and HIV prevalence
and concurrently a decrease of incidence and mortality of
HIV-infected patients over the period 2003–14. These
findings appear to confirm that spending on public health
for HIV management improves patients’ survival and pre-
vents new HIV infections.
However, in spite of the increase of total costs for HIV
infection care in the period (+25 % during the period),
Table 4 Per capita cost in HIV+ subjects according to 3-year-time periods
2003–2005 2006–2008 2009–2011 2012–2014
All HIV+ subjects (n) 2 846 3 211 3 604 3 855
Mean age (years) 40.7 42.9 45.1 47.2
Per capita cost (€)
Total 8 271 9 870 10 945 10 374
In-hospital 1 648 1 497 1 386 1 183
Antiretroviral therapy 5 079 6 685 7 876 7 562
Specialist services 1 649 1 695 1 605 1 544
Other 169 206 256 171
HIV+ subjects on ART (n) 1 975 2 421 2 854 3 130
Mean age (years) 41.6 43.7 45.9 47.8
Per capita cost (€)
Total 10 419 11 920 12 645 11 589
In-hospital 1 805 1 625 1 441 1 262
Antiretroviral therapy 6 796 8 393 9 342 8 612
Specialist services 1 649 1 695 1 605 1 544
Other 169 206 256 171
New HIV+ cases (n) 523 395 385 370
Mean age (years) 38.7 40.6 40.0 39.7
Per capita cost (€)
Total 7 978 7 838 10 040 9 731
In-hospital 4 048 3 666 4 699 4 421
Antiretroviral therapy 2 522 2 554 3 589 3 496
Specialist services 1 362 1 608 1 705 1 760
Other 46 10 48 54
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all chronic diseases in the Brescia LHA, HIV infection
maintained the third rank in order of cost per patient
since 2007 [10] to 2014 (present study).
A recent systematic review about economic impact of
HIV infection in five European countries showed a high
degree of inter-country variability, the HIV+ patients
cost ranging from 6 399€ in Italy and 11 638€ in Spain
to 25 339€ in UK and 32 109€ in Germany, ART being
the main component of total HIV health cost [17].
In the same line, the increase of total cost for HIV in
our study was entirely attributable to increase in ART
cost, mainly due to the proportion of patients on ART
increased +23 % over the period and because of intro-
duction of new antiretroviral drugs approved from 2005,
including new drugs within conventional classes as well
as novel drug classes. These newer antiretroviral drugs
are more effective in treatment of drug resistant HIV
but, on the other hand, are also more expensive than
those used previously, causing substantial incremental
costs [5, 6].
The cost of ART for HIV+ incident cases was around
half of that for all HIV+ patient across the period. Themain reasons for this is that cheaper drugs are more
commonly used in the first-line regimen than in the
following ART lines [18]. Indeed, various authors [6, 19]
have shown that the most powerful determinant of ART
cost was the line of ART. In our cohort, more than 70 %
of patients had used at least four lines of ART and 92 %
of patients on ART had plasmatic HIV RNA <37cp/ml.
(Data not shown in table). Furthermore, the complexity
of HIV+ patients plays an important role in cost of ART
including difficulty of achieving virological suppression
in ART experienced patients, toxicities, comorbidities
and drug-drug interaction thus contributing to the dif-
ferences in ART cost among centers also inside the same
country [6, 20].
In our study however, per capita costs for HIV+ patients
increased from 2003 to 2011 and decreased moderately
afterwards. This is probably due to the local public health
policy. Indeed, in the context of present austerity policies,
from 2011 the Lombardy Government has forced health
services to increase efficiency of resources allocation and
treatment appropriateness [Therapeutic and diagnostic
path-PDT- [21]]. As a consequence, HIV- specialists are
urged to the “economic efficacy principle” for choosing
Table 5 Association of chronic diseases, age, gender, period of follow-up and CD4+ cell count with per capita cost of care for HIV+
subjects using multivariate regression models
Per capita cost € (95 % CI) p-value
Age (per year) 36.1 (24.5–47.8) <0.001
Gender (male vs female) −12.5 (−198.6–173.6) 0.895
Period of follow-up
2003–2005 Ref
2006–2008 1473.4 (1215.8–1731.0) <0.001
2009–2011 2293.9 (2054.2–2533.6) <0.001
2012–2014 1453.0 (1207.8–1698.2) <0.001
CD4+ cell count
≥ 500 Ref
350–499 1272.0 (939.0–1605.1) <0.001
200–349 1082.6 (864.7–1300.4) <0.001
< 200 2452.3 (2238.7–2666.0) <0.001
Prevalence of chronic diseasesa
Cardio-cerebrovascular diseases (yes vs no) 2087.8 (1736.1–2439.5) <0.001
Liver diseases (yes vs no) 4388.8 (3786.0–4991.7) <0.001
Dyslipidemia (yes vs no) 1003.4 (593.2–1413.5) <0.001
Diabetes (yes vs no) 1701.4 (1125.0–2277.8) <0.001
Cancer (yes vs no) 7557.6 (6737.0–8378.2) <0.001
Gastrointestinal diseases (yes vs no) 3756.8 (2797.7–4715.8) <0.001
Neuropathies (yes vs no) 2767.6 (2081.9–3453.3) <0.001
Serious psychiatric diseases (yes vs no) 8172.2 (7056.0–9288.5) <0.001
Chronic respiratory diseases (yes vs no) 4103.3 (3192.4–5014.1) <0.001
Kidney failure (yes vs no) 13665.3 (11075.2–16255.5) <0.001
At least one chronic disease (yes vs no) 3699.7 (3509.9–3889.5) <0.001
amodel adjusted for age, gender, period of follow-up, CD4 cell count. Abbreviation: CI confidence interval
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generic drugs whenever available, according to PDT of the
Lombardy Health Service [21].
The increase of life expectancy of HIV+ patients in the
last decades due to efficacy of ART has determined
patients’ aging with consequent increase of comorbidities
and related health expenditure [9, 22]. HIV care involves
taking ART and having regular check-ups by healthcare
providers with opportunity for early diagnosis of co-
morbidities. Notwithstanding, HIV+ patients with comor-
bidities have poorer health outcomes than those without
comorbidities [23]. The prevalence of chronic diseases
was higher in HIV+ patients than in the LHA general
population, in agreement with other studies showing that
HIV+ patients have an early aging with a prevalence of
multi-comorbidities approximately equivalent to that
observed in the general population of 10–15 years older
[24, 25]. The prevalence of many “non-AIDS” chronic
diseases is inversely related to CD4+ cell count. This in-
cludes liver diseases [26], non-AIDS malignancies [27, 28]
and renal diseases [29]. Whereas, other diseases,particularly cardio-cerebrovascular diseases do not seem
to follow this pattern [30].
We observed a significant decreasing trend of the age
and gender adjusted prevalence of at least one chronic
disease adjusted for age and gender in HIV+ subjects over
time (annual mean change − 0.7 %; p = 0.006). One pos-
sible explanation for this is that continuous treatment of
HIV+ subjects in the period has determined an increase of
CD4+ cell levels with consequent decreasing comorbidity,
in agreement with the decrease of non-AIDS morbidity
concurrently with CD4+ cell level increase in some HIV+
cohorts [2–4].
Although prevalence of all chronic diseases in our HIV+
patients was higher than the general population, the
observed to expected ratio (SPR) for HIV+ subjects reduced
in the period, especially for liver diseases. At present, HCV
infection is the most common cause of chronic liver
diseases in both HIV+ patients and the general population
in Italy [31–33]. HIV/HCV coinfected subjects are less
frequently treated for HCV than HCV-monoinfected ones
due to higher difficulties to treat the formers due to
Quiros-Roldan et al. BMC Public Health  (2016) 16:1146 Page 9 of 10immunodeficiency, drug-drug interaction, low tolerability,
concomitant intravenous drug use or presence of psy-
chiatric diseases. Furthermore, in Italy HIV+ subjects have a
HIV reimbursement code allowing them to have whole
health care totally free, including HCV management and
cure. Therefore, HIV-HCV coinfected subjects do not ask
for HCV reimbursement code, and, as a consequence, they
are not detected by the LHA health database.
CD4+ cell count at baseline was inversely related with
per capita cost and this cost was particularly high in HIV+
subjects at advanced immunodeficiency stage, in agree-
ment with previous studies [6, 19, 34–36]. The Brescia
LHA health status database is a large, population-based
comprehensive and integrated information system which
has the usual limits of currently available large databases
of health data coming from various sources, leading to a
certain degree of imprecision in estimating the frequency
of chronic diseases and the cost of care of HIV+ subjects.
Anyway, a validation study and various analyses have
shown a fairly high quality of the database, especially as
regards the most common chronic diseases including
HIV, cardiovascular diseases, cancer and diabetes [37, 38].
As regards external validity, i.e. generalizability, the
HIV patients living in the Brescia LHA are substantially
similar to the national ones, in spite of a higher HIV
incidence in Brescia than in the whole country (10.8/
100000 vs 6.1/100 000 inhabitants). In fact, the HIV
cases with first diagnosis in 2014 are similar to those
described in the National reports in the same year as
regards demographic characteristics (79 % vs 80 %
males, mean age 38.8 vs 39 years, 23.8 % vs 27 %
non-Italian citizens) [39]. Likewise, as regards clinical as-
pects, the proportion of HIV incident cases with CD4
level <200 cell / mm3 in our cohort was similar to the
national one (33 % vs 35 %) [39].
Another possible limitation is that inflation has not
been accounted for. However, the official mean inflation
yearly rate in Italy in the period 2003–2104 has been
1.9 % (range: 0.2 % − 3.2 %) [40], hardly impacting on
our data and results.
This study has some strengths, too. First, it is
population-based allowing to estimate incidence, preva-
lence and mortality rates for all HIV+ subjects and all
residents living in the area and therefore avoiding
selection bias. Separate economic analyses could be per-
formed for incident and prevalent HIV+ cases whereas
most studies considered all HIV+ cases together. The
relatively long observation time (12 years) allowed us to
assess the temporal trend of the epidemiological pattern,
burden of chronic diseases, and overall and specific costs
of HIV+ subjects. Finally, all HIV+ patients have been
cured in the unique Infectious Diseases Unit in the area,
allowing the collection of clinical data and matching
them with the LHA data base.Conclusions
Our findings suggest that spending on public health for
HIV care can improve prognosis of HIV-infected
patients, reduce transmission of HIV infection and re-
duce the global burden of chronic diseases, leading to a
reduction of HIV global cost in the medium-long time.
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